Been thinking about how vaccine stocks evolved as an investment theme, and it's actually a pretty interesting case study for understanding market dynamics.

Back in 2020, if you wanted to invest in covid vaccine stocks, you were basically making a high-risk bet on pure speculation. Companies like Moderna and Novavax were in early trial phases - we had no idea if their candidates would even work. But for those who could stomach the volatility, the payoff was massive. Moderna jumped over 600% that year, Novavax went up more than 3000%. Wild times.

But here's the thing - the game completely changed once we moved into 2021. Once vaccine candidates started hitting phase 3 trials and regulatory approvals looked real, the investment calculus shifted. It wasn't about "will this work?" anymore. It became "when will this generate revenue?" and "how much will it make?"

I think this teaches us something important about how to invest in vaccine stocks or any biotech play. Early stage is high risk, high reward - but it's basically gambling with better odds. Once you get to late-stage trials and regulatory approval is in sight, the risk profile changes dramatically. You're no longer betting on whether something works; you're betting on execution and revenue generation.

The other shift was about who could participate. In 2020, this was aggressive investor territory only. These companies had no other revenue streams, so everything depended on the vaccine bet. But as we moved forward, even more conservative investors could find opportunities - maybe smaller positions in companies closer to approval, or waiting for actual revenue numbers before jumping in.

Looking back now, what's interesting is how the broader investment thesis held up. The companies that made it through to approval and revenue generation did continue to see gains. It wasn't the explosive 600% moves anymore, but it was steady. That's actually a more sustainable pattern for most investors.

The key takeaway for anyone thinking about how to invest in vaccine stocks or similar biotech plays: understand what stage you're buying into. Early stage programs? That's a completely different risk-return profile than late-stage candidates. Know which one you're actually taking on, and size your position accordingly. That's the real lesson from how this whole thing played out.